EMA Highlights: Green light for rare cancer treatments
by Gary Finnegan: Survival rates in young patients with high-risk neuroblastoma can be improved by Unituxin (dinutuximab), a new treatment approved by the European Medicines Agency (EMA).
by Gary Finnegan: Survival rates in young patients with high-risk neuroblastoma can be improved by Unituxin (dinutuximab), a new treatment approved by the European Medicines Agency (EMA).
by Bruce Sylvester: Investigators from the phase III PALOMA-3 trial report that treatment with the recently FDA-approved drug palbociclib more than doubled the time to cancer recurrence among… read more.
by Bruce Sylvester: Treatment of advanced melanoma with a combination of nivolumab (Opdivo™) and ipilimumab (Yervoy™) or with nivolumab alone increases progression-free survival over ipilimumab monotherapy, researchers reported… read more.
by Bruce Sylvester: Anastrozole is significantly more effective than tamoxifen in preventing cancer recurrence after lumpectomy and radiation therapy in postmenopausal women, age 60 or younger with DCIS… read more.
by Bruce Sylvester: Pembrolizumab (Keytruda®), an anti-PD-1 antibody immunotherapy has shown efficacy in one fourth of patients with recurrent or metastatic head and neck cancer, researchers reported on… read more.
by Bruce Sylvester: In a Phase III trial comparing standard docetaxel chemotherapy with immunotherapy nivolumab, researchers reported that subjects with squamous-non-small cell lung cancer treated with nivolumab lived… read more.
Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek… read more.
Results highlight importance of pre-test counselling for at-risk patient populations. Some at-risk patients opted out of comprehensive cancer gene screening when presented with the opportunity to be tested… read more.
by Bruce Sylvester: Lung cancer patients whose tumors carry specific mutations in the BRAF gene appear to benefit from drugs used to treat melanoma, researchers from the retrospective… read more.
by Bruce Sylvester: Researchers from a phase 3, randomized trial of brentuximab vedotin report that adults with hard-to-treat Hodgkin lymphoma treated with brentuximab vedotin immediately after stem cell… read more.
by Bruce Slyvester: Among a large group of women who carry disease-associated mutations in BRCA1 or BRCA2 genes, genetic mutations appear to be associated with significantly different risks of developing breast… read more.
by Bruce Sylvester: Diabetes and advanced stage breast cancer appear to be linked and diabetic women need better screening, Canadian researchers reported online on March 24, 2015 in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.